Incyte (INCY) is an innovative pharmaceutical company that had its stock price peak at $140.11 in 2017 when it was considered to be a likely acquisition target. Most recently a drug it developed and licensed to Eli Lilly (LLY), Olumiant or baricitinib, showed promise as a treatment for COVID-19. While not to be neglected, this indication pales in significance to other therapies likely to increase Incyte's revenue and profits. Given its current commercially approved drugs, and its pipeline of potential therapies, I believe Incyte is currently priced attractively for longer